Osborne says Tories could raise NHS spending

Chancellor hints party could plug £8bn annual gap in next parliament

Industry response to Ebola quickens

Drugmakers to be offered indemnity for new vaccine

Andrew Ballheimer, Sara Pickersgill and Claire Coppel (blonde hair) from Allen & Overy. Photograph: Rosie Hallam

Three generations in one office

Millennial, Generation X and baby-boomer colleagues on their jobs

NHS chief seeks inflation-plus spending

Funding needs to keep pace with ageing population, says Stevens

Witty goes some way to disarm gainsayers

Better news on drug pipelines still needed to pacify doubters

Mylan tweaks $5bn ‘inversion’ deal

Drugs maker pushes on with Abbott unit purchase that will cut tax rate

GSK’s chief Witty comes out fighting

Drugmaker ‘extremely pragmatic’ about options for boosting value

Ebola vaccine doses expected this year

GSK anticipates initial supply to be available in two months

GSK looks at potential float of HIV unit

Cost-cutting and multibillion-pound restructuring drive launched

Amgen: splitting hairs

Amgen is not a conglomerate. Breaking it up is pure valuation arbitrage

Loeb urges Amgen to explore a break-up

Activist investor says the biotech company is trading at a ‘substantial discount’ to its peers

A modern plague spread by love and fear

Vaccines and drugs are unlikely to save west Africa from Ebola

Life sciences seek angel investors

MedCity project aims to establish London as hub for medical research

Shire CFO jumps ship for Severn Trent

Departure adds to disruption for drugs group

Valeant hints at higher bid for Allergan

Pharma group plays down talks of split with Pershing Square

14 Care UK homes face investigation

Private equity-owned healthcare business also under strike threat

AbbVie hits at Treasury as Shire deal dies

González calls for comprehensive US tax reform

UK backs unlicensed medicines bill

New drugs for terminally ill would help cure cancer, says Saatchi

To stop ‘deserters’, reform tax system

Rhetoric alone will not inspire companies to pay more in taxes

M&A deal failure at highest since 2008

A total of $573bn worth of deals have been withdrawn so far, compared with $640bn in 2008


More FT Twitter accounts